Logo

financial results

Gilead Expects Continued Competitive Pressure in 2025 for Cell Therapy Products
Premium

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

AstraZeneca Optimistic About Phase III Camizestrant Data in 2025, Reports Strong Q4 Product Growth
Premium

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Bristol Myers Squibb Focused on Opdivo SubQ Growth as Q4 Precision Product Sales Increase
Premium

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Amgen Reports More Than $2B in Oncology Revenues in Q4

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Merck Talks Up Pipeline Diversification as Demand for Keytruda, Facing Patent Expirations, Grows
Premium

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Feb 4, 2025

Pfizer Reports 27 Percent Oncology Growth in Q4, Touts Progress in ADC and Breast Cancer Trials
Premium

Jan 31, 2025

Novartis Posts Strong Q4 Sales of Kisqali, Pluvicto

Jan 22, 2025

J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4

Nov 12, 2024

AstraZeneca Reports Q3 Revenue Growth for Precision Cancer Drugs Amid Ongoing China Investigations
Premium

Nov 7, 2024

Gilead Sciences Focuses on New Multiple Myeloma CAR T Amid Flat Q3 Cell Therapy Sales
Premium

Oct 31, 2024

Merck Talks Up Pipeline Diversification as Keytruda Sales Still Comprise 45 Percent of Q3 Revenues
Premium

Oct 31, 2024

BMS Anticipates New Opdivo Formulation Approval as CAR T, Targeted Therapy Sales Jump in Q3
Premium

Oct 31, 2024

Amgen Sees Strong Growth for Precision Oncology Drugs in Q3

Oct 29, 2024

Novartis Sees Steady Q3 Pluvicto Sales Growth as it Readies to Triple Eligible Population in 2025
Premium

Oct 29, 2024

Pfizer Highlights Upcoming Trial Readouts in Cancer as Oncology Unit Growth Continues in Q3
Premium

Oct 23, 2024

Roche Sees Strong Demand for Elevidys Gene Therapy Amid Steady Q3 Pharmaceutical Revenue Growth
Premium

Oct 15, 2024

Sales of J&J's Carvykti Surge Amid Expansion of Manufacturing Capacity
Premium

Aug 13, 2024

Grail to Cut Headcount by 30 Percent in Restructuring, Reports 43 Percent Q2 Revenue Rise

Aug 12, 2024

Lucid Diagnostics' Esophageal Precancer Test Sales Spike in Q2

Aug 7, 2024

Amgen Invests in Late-Stage Pipeline as Q2 Revenues Grow 20 Percent
Premium

Jul 30, 2024

Pfizer Oncology Product Revenues Jump 26 Percent in Q2

Jul 30, 2024

Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates

Jul 26, 2024

BMS Reports 53 Percent Increase in Q2 Breyanzi Sales
Premium

Jul 25, 2024

Roche Reports 5 Percent CER Growth in Pharmaceutical Sales Driven by Strong Phesgo Uptake

Jul 25, 2024

AstraZeneca Reports Encouraging Uptake of New Breast Cancer Drug Truqap in First Half of 2024
Premium